PubRank

Peter Mesenbrink

Author PubWeight™ 51.44‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007 18.27
2 Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007 9.83
3 Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med 2005 3.57
4 Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2009 3.16
5 Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc 2008 2.75
6 Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int 2008 2.29
7 Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res 2008 2.04
8 Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res 2010 1.54
9 Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture. J Bone Miner Res 2009 1.17
10 Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. J Am Geriatr Soc 2010 1.16
11 The HORIZON Recurrent Fracture Trial: design of a clinical trial in the prevention of subsequent fractures after low trauma hip fracture repair. Curr Med Res Opin 2004 1.15
12 Effects of antiresorptive treatment on nonvertebral fracture outcomes. J Bone Miner Res 2011 1.05
13 Potential mediators of the mortality reduction with zoledronic acid after hip fracture. J Bone Miner Res 2010 0.99
14 Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial. Obstet Gynecol 2009 0.92
15 Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density. J Clin Endocrinol Metab 2009 0.91
16 Rivastigmine in Alzheimer disease: efficacy over two years. Am J Geriatr Psychiatry 2004 0.84
17 Time to onset of antifracture efficacy and year-by-year persistence of effect of zoledronic acid in women with osteoporosis. J Bone Miner Res 2012 0.79
18 Subgroup variations in bone mineral density response to zoledronic acid after hip fracture. J Bone Miner Res 2014 0.76
19 Once-yearly zoledronic acid and days of disability, bed rest, and back pain: randomized, controlled HORIZON Pivotal Fracture Trial. J Bone Miner Res 2011 0.75
20 Zoledronic Acid in Reducing Clinical Fracture and Mortality after Hip Fracture. N Engl J Med 2007 0.75